Kailera Therapeutics reported second quarter 2026 financial results and business updates, highlighting progress across its obesity pipeline.
The company reports an active IND for ribupatide oral, with initiation of global Phase 3 obesity trials planned for the first half of 2027, and says its ribupatide injection Phase 2b high-dose obesity trial is fully enrolled with data anticipated in mid-2027; global Phase 3 KaiNETIC enrollment is on track for more than 4,700 participants with data expected in 2028.
Kailera reported cash, cash equivalents and marketable securities of $1,171.8 million as of 30 June 2026, which the company expects will fund operations into mid-2028, according to the company. Research and development expense was $101.1 million for the quarter and general and administrative expense was $20.3 million; net loss was $111.3 million for the quarter ended 30 June 2026.
The company also announced senior leadership additions and said it was added to the Russell 2000 Index effective 29 June 2026.
